SCHEMBL13664230

SCHEMBL13664230

N#Cc1c(C(=O)Cc2ccccc2)nn(-c2ccc(Cl)cc2)c1N

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
GAA P10253 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
POLB P06746 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
TSHR P16473 1/20 0.45
LMNA P02545 3/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 1/20 0.44
ABCB1 P08183 3/20 0.43
MALT1 Q9UDY8 1/20 0.41
CNR1 P21554 2/20 0.41
KDM4E B2RXH2 3/20 0.40
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
THRB P10828 1/20 0.39
CNR2 P34972 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13667968 0.84 MAPT (0.49) MAPTSMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL13664174 0.82 MAPT (0.52) MAPTSMN1; SMN2MEN1KMT2AGAA
SCHEMBL13664235 0.80 MAPT (0.49) MAPTSMN1; SMN2MEN1KMT2AGAA
SCHEMBL13664246 0.79 MAPT (0.48) MAPTSMN1; SMN2MEN1KMT2AGAA
SCHEMBL13664213 0.79 MAPT (0.48) MAPTSMN1; SMN2MEN1KMT2AGAA
SCHEMBL13664245 0.78 MAPT (0.47) MAPTSMN1; SMN2MEN1KMT2AGAA
SCHEMBL13664217 0.76 MAPT (0.49) MAPTSMN1; SMN2MEN1KMT2AGAA
SCHEMBL13664233 0.76 MAPT (0.46) MAPTSMN1; SMN2MEN1KMT2AGAA
SCHEMBL12100341 0.76 KDM4E (0.60) MAPTSMN1; SMN2MEN1KMT2AGAA
SCHEMBL13664223 0.75 MAPT (0.52) MAPTSMN1; SMN2MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists MERCK SHARP & DOHME CORP. 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists GIPR, GPR119, GLP1R MAPT 4701/4885SMN1; SMN2 3698/4885MEN1 3462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.